AUTL · Autolus Therapeutics plc
$2.41
-0.05 (-2.03%)
At close · Aug 21
Market Cap
$641.45M
Shares
266.16M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$2.41
Open$2.47
Day$2.40–2.51
52W close$1.21–2.54
Avg vol 30d2.7M
Short int13.8M · 5.2% float · 16.6d
Short vol16%
Last earningsAug 11, 2026
DataJan 2020–Aug 2026
Filing10-Q · Aug 11
Up next
Next earnings call
Nov 10, 2026
Est · unconfirmed
· in 11 wks
FQ3-26 quarter ends
~Sep 30, 2026
Est
filed Aug 11, 2026
AI Brief
TL;DR.
Bullish
Bearish
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ask ALVIS about this →Equibles Rating
blended score · not investment adviceOverall
Buy
SellHoldBuy
Technical
Strong Buy
Momentum
Very Strong
Sentiment
Neutral
Fundamentals
Fair
Quant / Vol
Very High
Market backdrop
VIX 15.1 · calm
Equity put/call 0.51
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+53%
above
Price vs 50-day avg
+39%
above
RSI (14)
67
neutral
MACD trend
Positive
52-week position
90%
near high
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
+66%
trailing
6-month return
+44%
trailing
YTD return
+21%
this year
Relative strength
+33%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.18% of float · ▼ -8.9% MoM · 16.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
84 holders — mid 3-yr range
Squeeze score
87
high risk · 0–100
Fundamentals
Revenue growth
+496%
Y/Y
EPS growth
−26%
Y/Y
Free cash flow
$-302.6M
Balance sheet
$104.1M
net cash
Quant / Vol
risk profile
Volatility
80%
annualized · 1-yr
Max drawdown
−40%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Latest guidance
· from the 8-K filed May 14, 2026
AUCATZYL net product revenue
· full year 2026
$120M – $135M
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders Strong Buy
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+53%
Bullish
Price vs 50-day avg
+39%
Bullish
RSI (14)
67
Neutral
MACD trend
Positive
Bullish
52-week position
90%
Bullish
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 1 of 6
Trend (MA cross)
No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow
Flat
0% holders QoQ · +10 funds added
Insider flow
Flat
No net insider activity over 90 days
Short interest
Falling
5.18% of float · ▼ -8.9% MoM · 16.6 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Steady
84 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1
Now $2 · 90%
Range high $3
vs 200-day avg +53%
vs 50-day avg +39%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| AUCATZYL Global Net Product Revenue | $71.9M | 1H 2026 | — |
|
|
|||
| Gross margin | 55% | Q2 2026 | — |
| U.S. Authorized Treatment Centers | 82 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
AUTL
this stock
Autolus Therapeutics plc
|
$641.45M | +21.1% | +496.0% | — | 5.2% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$138.91B | +20.9% | +46.2% | 31.9 | 1.6% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$85.87B | +8.1% | +20.8% | 20.7 | 3.3% |
|
ARGX
Argenx SE
|
$64.66B | +23.6% | — | — | 2.1% |
|
CSLLY
Csl Ltd
|
$57.97B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| AUTL | +12.1% | +66.2% | +44.3% | +61.7% | +21.1% |
| SPY | -1.4% | +3.6% | +11.6% | +2.5% | +12.3% |
| vs SPY | +13.5% | +62.6% | +32.8% | +59.2% | +8.8% |
Key facts
CIK
1730463
CUSIP
05280R100
13F (30d)
76 filings
75 filers
Visit website
Investor relations